The study findings demonstrate diverse neurodevelopmental profiles in treated children with/at-risk of spinal muscular atrophy type 1 associated with the magnitude and duration of SMN deficiency. This evidence concerns the gene SMN2 and spinal muscular atrophy, type 1.